AptaBio Therapeutics Inc Asset Resilience Ratio
AptaBio Therapeutics Inc asset resilience ratio. AptaBio Therapeutics Inc (293780) has an Asset Resilience Ratio of 1.57% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can AptaBio Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of AptaBio Therapeutics Inc (2017–2024)
Asset resilience ratio of AptaBio Therapeutics Inc from 2017 to 2024. This chart shows how AptaBio Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of AptaBio Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down AptaBio Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 293780 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.05 Billion | 1.57% |
| Total Liquid Assets | ₩1.05 Billion | 1.57% |
Asset Resilience Insights
- Limited Liquidity: AptaBio Therapeutics Inc maintains only 1.57% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
AptaBio Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare AptaBio Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
AptaBio Therapeutics Inc Asset Resilience Ratio by Year (2017–2024)
AptaBio Therapeutics Inc asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for AptaBio Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.71% | ₩5.97 Billion ≈ $4.05 Million |
₩77.43 Billion ≈ $52.48 Million |
-22.41pp |
| 2023-12-31 | 30.12% | ₩27.87 Billion ≈ $18.89 Million |
₩92.52 Billion ≈ $62.70 Million |
+3.34pp |
| 2022-12-31 | 26.78% | ₩15.03 Billion ≈ $10.18 Million |
₩56.11 Billion ≈ $38.03 Million |
-8.52pp |
| 2021-12-31 | 35.30% | ₩22.91 Billion ≈ $15.53 Million |
₩64.91 Billion ≈ $43.99 Million |
-21.47pp |
| 2020-12-31 | 56.76% | ₩42.82 Billion ≈ $29.02 Million |
₩75.44 Billion ≈ $51.13 Million |
-2.87pp |
| 2019-12-31 | 59.63% | ₩46.16 Billion ≈ $31.28 Million |
₩77.40 Billion ≈ $52.46 Million |
-37.25pp |
| 2018-12-31 | 96.88% | ₩19.69 Billion ≈ $13.35 Million |
₩20.33 Billion ≈ $13.78 Million |
+0.80pp |
| 2017-12-31 | 96.08% | ₩10.57 Billion ≈ $7.16 Million |
₩11.00 Billion ≈ $7.46 Million |
-- |
About AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more